II. Drug Resistance accross G/Ps.
NGYX I.C. Comment(s): There are numerous Phenotypic results (various sources) that fail to be discriminative at both Sensitive/Resistance sides (numerous measurements are under/over the lower/upper limit of the detection range). Definitively EFV would have been beneficial to have data from an extended Test Dynamic Range.
III. Additional Remarks.
A. EFV is rated at 65% on the NGYX I.C.Scale of Drug Resistance Interest (DRI). This means that each couple of G/P is valuable maximally for 0.65 Euros. If you want to know more about DRI Click HERE.
B. Combining subsets will impact the number of variables (mutations / clades) that NGIX I.C. classify as "ACCEPTED". T0 know more about this Click HERE.